What is HC Wainwright’s Forecast for ALNY FY2024 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Alnylam Pharmaceuticals in a report issued on Monday, November 4th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will earn ($2.24) per share for the year, up from their prior forecast of ($2.31). HC Wainwright has a “Buy” rating and a $400.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.71) EPS, FY2026 earnings at $9.23 EPS, FY2027 earnings at $19.05 EPS and FY2028 earnings at $22.41 EPS.

A number of other research analysts also recently issued reports on ALNY. Cantor Fitzgerald restated a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Barclays increased their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Scotiabank lifted their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Finally, Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a research report on Friday, July 12th. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $294.50.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $272.22 on Thursday. The stock’s 50-day moving average is $273.88 and its two-hundred day moving average is $229.34. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter last year, the business earned $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. Huntington National Bank increased its position in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. Ashton Thomas Private Wealth LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $26,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the third quarter worth about $42,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.